先声药业(02096.HK)SIM0610获药物临床试验批准通知书

Core Viewpoint - The company, Sihuan Pharmaceutical (02096.HK), has received approval from the National Medical Products Administration of China for clinical trials of its self-developed bispecific antibody-drug conjugate candidate SIM0610, aimed at treating patients with locally advanced or metastatic solid tumors [1] Group 1 - The candidate drug SIM0610 is a bispecific antibody-drug conjugate (BsADC) [1] - The clinical trials will focus on patients with locally advanced or metastatic solid tumors [1]